E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
metastatic renal cell carcinoma |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10050018 |
E.1.2 | Term | Renal cancer metastatic |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare PFS of enzastaurin plus sunitinib therapy versus placebo plus sunitinib in the first-line setting for patients with metastatic clear-cell RCC. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of the study are: to compare the following time-to-event efficacy variables between treatment arms: ○ overall survival (OS) ○ time-to-tumor progression (TTP) to estimate duration of overall response in each treatment arm to compare the overall response rate (complete response [CR] + partial response [PR]) between treatment arms using standard RECIST criteria (as described in Protocol Attachment S061.7) to compare the rate of clinical benefit (CR + PR + stable disease [SD]) between treatment arms to assess the safety and adverse events in both treatment arms to characterize the pharmacokinetics (PK) of enzastaurin and sunitinib when administered in combination to assess biomarkers (for example, PKCβ, GSK3β, S6K, PTEN, CREB) relevant to enzastaurin and disease state, and their correlation to clinical outcome. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
FARMACOGENETICA FARMACOCINETICA/FARMACODINAMICA |
|
E.3 | Principal inclusion criteria |
1. Patients with metastatic RCC who have not received prior treatment with systemic (adjuvant or neoadjuvant) therapy for RCC (including targeted therapy such as tyrosine kinase inhibitors or bevacizumab, immunotherapy, chemotherapy, hormonal, or investigational therapy) 2. Histologically confirmed RCC with metastases with a component of clear (conventional) cell histology 3. Evidence of unidimensionally measurable disease (≥1 malignant tumor mass that can be accurately measured in at least 1 dimension ≥20 mm with conventional computed tomography (CT) or magnetic resonance imaging (MRI) scan, or ≥10 mm with spiral CT scan. (If spiral CT scan is used, minimum lesion size should be twice the reconstruction interval used. For example, if reconstruction size is 7 mm, lesion size should be ≥14 mm). CT/MRI should be performed within 4 weeks prior to study entry Note: Bone lesions, ascites, peritoneal carcinomatosis or miliary lesions, pleural or pericardial effusions, lymphangitis of the skin or lung, cystic lesions, or irradiated lesions are not considered measurable. 4. Primary tumor has been surgically removed by nephrectomy or nephron-sparing surgery 5. ECOG performance status score of 0 or 1 6. Have adequate bone marrow, liver, and renal function 7. Patients must be at least 18 years of age 8.Women of childbearing potential (not surgically sterilized and between menarche and 1 year postmenopause) must test negative for pregnancy within 7 days prior to or at the time of enrollment, based on either a serum or urine pregnancy test. Both male and female patients of reproductive potential must agree to use a reliable method of birth control, as determined by the patient and his or her health-care team, during the study and for 3 months following the last dose of study treatment 9. No prior malignancies for ≥5 years with the exception of cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis, and T1) or any cancer curatively treated ≥5 years prior to study entry. |
|
E.4 | Principal exclusion criteria |
1. Have received prior treatment with sunitinib or enzastaurin 2. Have history of or known brain metastases, spinal cord compression, carcinomatous meningitis, or evidence of brain or leptomeningeal disease on screening CT or MRI scan 3. Have history of documented central nervous system disease unrelated to cancer; for example, uncontrolled seizures, unless adequately treated with standard medical therapy 4.Have evidence of bleeding diathesis, NCI CTCAE Grade 3 hemorrhage <4 weeks of starting the study treatment, coagulopathy, or thromboembolic event 5.Have uncontrolled hypertension (>150/100 mm/Hg despite optimal medical therapy), or history of poor compliance with antihypertensive treatment. 6. Require concomitant use of potent CYP3A4 inducer, for example, rifampicin or potent CYP3A inhibitors, such as ketoconazole. Note: Protocol Attachment S061.4 provides an extensive list of CYP3A4 inhibitors or inducers. 7. Have impairment of the gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug. 8. Current or recent (within 10 days of first dose of study treatment) daily use of aspirin (>325 mg/day) 9.Patients who are pregnant or breast feeding. 10. Have any condition that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study (for example, uncontrolled diabetes mellitus, pancreatitis, acute or chronic liver disease), and preexisting thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Progression-free survival is defined as the time from the date of study enrollment to the first date of objectively determined progressive disease (PD) or death from any cause. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Ultima visita dell'ultimo paziente in studio |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |